卵巢癌中的PI3K-AKT-mTOR和NFκB信号通路：对靶向治疗的启示
PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics.
作者信息
Ghoneum Alia, Said Neveen
机构信息
Departments of Cancer Biology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA.
Departments of Cancer Biology, Pathology, and Urology, Wake Forest University School of Medicine, Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC 27157, USA.
出版信息
Cancers (Basel). 2019 Jul 5;11(7):949. doi: 10.3390/cancers11070949.
Abstract
Ovarian cancer is the most lethal gynecologic malignancy in the United States, with an estimated 22,530 new cases and 13,980 deaths in 2019. Recent studies have indicated that the phosphoinositol 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), as well as the nuclear factor-κ light chain enhancer of activated B cells (NFκB) pathways are highly mutated and/or hyper-activated in a majority of ovarian cancer patients, and are associated with advanced grade and stage disease and poor prognosis. In this review, we will investigate PI3K/AKT/mTOR and their interconnection with NFκB pathway in ovarian cancer cells.
摘要
卵巢癌是美国最致命的妇科恶性肿瘤，2019年估计有22,530例新发病例和13,980例死亡病例。最近的研究表明，磷脂酰肌醇3激酶（PI3K）/蛋白激酶B（AKT）/雷帕霉素哺乳动物靶蛋白（mTOR）以及活化B细胞核因子κB轻链增强子（NFκB）通路在大多数卵巢癌患者中高度突变和/或过度激活，并且与高级别和晚期疾病以及不良预后相关。在本综述中，我们将研究卵巢癌细胞中PI3K/AKT/mTOR及其与NFκB通路的相互联系。
相似文献
1
PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics.
Cancers (Basel). 2019 Jul 5;11(7):949. doi: 10.3390/cancers11070949.
2
Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer.
Cancer Drug Resist. 2021 Apr 14;4(3):573-595. doi: 10.20517/cdr.2021.05. eCollection 2021.
3
Targeting the PI3K/AKT/mTOR/NFκB Axis in Ovarian Cancer.
J Cell Immunol. 2020;2(2):68-73. doi: 10.33696/immunology.1.022.
4
The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
Gynecol Oncol. 2021 Nov;163(2):433-444. doi: 10.1016/j.ygyno.2021.07.008. Epub 2021 Jul 10.
5
Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics.
PLoS One. 2015 Nov 16;10(11):e0141253. doi: 10.1371/journal.pone.0141253. eCollection 2015.
6
Compound C Inhibits Ovarian Cancer Progression via PI3K-AKT-mTOR-NFκB Pathway.
Cancers (Basel). 2022 Oct 18;14(20):5099. doi: 10.3390/cancers14205099.
7
Melatonin suppresses serum starvation-induced autophagy of ovarian granulosa cells in premature ovarian insufficiency.
BMC Womens Health. 2022 Nov 24;22(1):474. doi: 10.1186/s12905-022-02056-7.
8
Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway.
Eur Rev Med Pharmacol Sci. 2018 Dec;22(23):8135-8144. doi: 10.26355/eurrev_201812_16505.
9
PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.
Arch Gynecol Obstet. 2014 Dec;290(6):1067-78. doi: 10.1007/s00404-014-3377-3. Epub 2014 Aug 3.
10
A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
BJU Int. 2012 Dec;110(11 Pt C):E1237-48. doi: 10.1111/j.1464-410X.2012.11569.x. Epub 2012 Oct 29.
引用本文的文献
1
Signaling networks and MiRNA crosstalk in ovarian cancer chemoresistance.
J Ovarian Res. 2025 Aug 14;18(1):185. doi: 10.1186/s13048-025-01770-8.
2
From lab to life: technological innovations in transforming cancer metastasis detection and therapy.
Discov Oncol. 2025 Aug 10;16(1):1517. doi: 10.1007/s12672-025-02910-8.
3
Assessing Auranofin for Second-Line Use in Chemoresistant Ovarian Cancer: Effects on Tumour Spheroid and Primary Cell Growth.
J Cell Mol Med. 2025 Jul;29(13):e70681. doi: 10.1111/jcmm.70681.
4
The protease ADAMTS5 controls ovarian cancer cell invasion, downstream of Rab25.
FEBS J. 2025 Sep;292(17):4491-4515. doi: 10.1111/febs.70080. Epub 2025 Mar 31.
5
Advanced Therapeutic Approaches for Metastatic Ovarian Cancer.
Cancers (Basel). 2025 Feb 25;17(5):788. doi: 10.3390/cancers17050788.
6
miR-21-5p Targets PIK3R1 to Regulate the NF-B Signaling Pathway, Inhibiting the Invasion and Progression of Prolactinoma.
Int J Endocrinol. 2025 Feb 5;2025:7741091. doi: 10.1155/ije/7741091. eCollection 2025.
7
Molecular pathways in reproductive cancers: a focus on prostate and ovarian cancer.
Cancer Cell Int. 2025 Feb 3;25(1):33. doi: 10.1186/s12935-025-03658-5.
8
Loss of phosphatase and tensin homolog () increases Lysyl oxidase-like 2 () expression enhancing the growth of fallopian tube epithelial cells as three-dimensional spheroids.
Cancer Pathog Ther. 2024 Mar 26;3(1):68-75. doi: 10.1016/j.cpt.2024.03.003. eCollection 2025 Jan.
9
Exploring Strategies to Prevent and Treat Ovarian Cancer in Terms of Oxidative Stress and Antioxidants.
Antioxidants (Basel). 2025 Jan 20;14(1):114. doi: 10.3390/antiox14010114.
10
NOS inhibition sensitizes metaplastic breast cancer to PI3K inhibition and taxane therapy via c-JUN repression.
Nat Commun. 2024 Dec 30;15(1):10737. doi: 10.1038/s41467-024-54651-x.
本文引用的文献
1
Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma.
mBio. 2019 Feb 19;10(1):e02871-18. doi: 10.1128/mBio.02871-18.
2
A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
Gynecol Oncol. 2019 Apr;153(1):135-148. doi: 10.1016/j.ygyno.2019.01.012. Epub 2019 Jan 25.
3
Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer.
Oncologist. 2019 Mar;24(3):305-312. doi: 10.1634/theoncologist.2018-0314. Epub 2019 Jan 16.
4
Impact of p85α Alterations in Cancer.
Biomolecules. 2019 Jan 15;9(1):29. doi: 10.3390/biom9010029.
5
Cancer statistics, 2019.
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
6
Co-delivery of curcumin and doxorubicin in PEGylated liposomes favored the antineoplastic C26 murine colon carcinoma microenvironment.
Drug Deliv Transl Res. 2019 Feb;9(1):260-272. doi: 10.1007/s13346-018-00598-8.
7
Tumor evolution and chemoresistance in ovarian cancer.
NPJ Precis Oncol. 2018 Sep 17;2:20. doi: 10.1038/s41698-018-0063-0. eCollection 2018.
8
PAK5 Induces EMT and Promotes Cell Migration and Invasion by Activating the PI3K/AKT Pathway in Ovarian Cancer.
Anal Cell Pathol (Amst). 2018 Sep 2;2018:8073124. doi: 10.1155/2018/8073124. eCollection 2018.
9
Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date.
Onco Targets Ther. 2018 Aug 13;11:4817-4827. doi: 10.2147/OTT.S142264. eCollection 2018.
10
Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies.
Acta Pharm Sin B. 2018 Jul;8(4):518-529. doi: 10.1016/j.apsb.2018.04.007. Epub 2018 Apr 30.
Zotero 插件